Alemtuzumab
Prijeđi na navigaciju
Prijeđi na pretragu
| |
| Klinički podaci | |
|---|---|
| Robne marke | Campath, Campath (ILEX Pharmaceuticals LP), MabCampath |
| AHFS/Drugs.com | Monografija |
| Identifikatori | |
| CAS broj | 216503-57-0 |
| ATC kod | L01XC04 |
| DrugBank | DB00087 |
| ChEMBL[1] | CHEMBL1201587 
|
| Hemijski podaci | |
| Formula | C6468H10066N1732O2005S40 |
| Mol. masa | 145453.8 |
| Fizički podaci | |
| Tačka topljenja | 61 °C (142 °F) |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | ~288 h |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| Način primene | Intravenozno |
Alemtuzumab (Campath, MabCampath, Campath-1H, Lemtrada) humanizovano je monoklonalno antitelo specifično za limfocitne antigene. Alemtuzumab je rekombinantno monoklonalno antitelo (Campath-1H) koje prepoznaje glikoprotein CD52. Campath-1H antitelo je IgG1 kapa sa ljudskim varijablnim okvirom i konstantnim regionima, i regionima komplementarinosti iz pacovskog monoklonalnog antitela (Campath-1G). Alemtuzumab se koristi u lečenju hronične limfatične leukemije (CLL), kožnog T ćelijskog limfoma (CTCL) i T-ćelijskog limfoma.[2][3][4][5][6][7][8]
Reference[uredi | uredi kod]
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983 Oct;62(4):873-82. PMID 6349718
- ↑ Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323-7. PMID 3127726
- ↑ IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1BEY Arhivirano 2008-12-07 na Wayback Machine-u
- ↑ IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CE1 Arhivirano 2008-12-07 na Wayback Machine-u
- ↑ IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=8005 Arhivirano 2008-12-07 na Wayback Machine-u
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
- ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
Literatura[uredi | uredi kod]
- Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
- Thomas L. Lemke, David A. Williams, ur. (2007). Foye's Principles of Medicinal Chemistry (6 izd.). Baltimore: Lippincott Willams & Wilkins. ISBN 0-7817-6879-9.
